Literature DB >> 15828924

Effect over time of endotoxin adsorption therapy in sepsis.

Takuya Ueno1, Michio Sugino, Hiromu Nemoto, Hisataka Shoji, Akira Kakita, Masahiko Watanabe.   

Abstract

Despite the use of potent antibiotics and intensive supportive care, the mortality among patients with sepsis and Gram-negative bacteremia remains high. In recent years, endotoxin adsorption therapy (PMX-DHP, polymyxin-direct hemoperfusion) has been widely used in Japan to remove endotoxin, a causative agent of sepsis. In septic patients whose clinical condition may change at any moment, the decision of when to perform blood purification in addition to conventional intensive care is a critical factor in the therapeutic strategy and prognosis. In the present study, we investigated the effect over time of PMX-DHP in sepsis. The subjects were 16 patients with systemic inflammatory response syndrome (SIRS) who required surgical treatment including a surgical operation and drainage. The following six parameters were compared between the first and second PMX-DHP: mean blood pressure and time-restricted urine at four time points - at baseline and at 6, 24 and 72 h after PMX-DHP; and white blood cell count, platelet count, base excess and Septic Severity Score (SSS) at 24 and 72 h after PMX-DHP. Mean blood pressure improved over time up to 24 h after both the first and second PMX-DHP. Time-restricted urine volume improved only at 6 h after the first PMX-DHP. White blood cell count improved over time up to 24 h after both the first and second PMX-DHP. The SSS improved at all time points studied except for 3 days after the second PMX-DHP. We conclude that PMX-DHP is expected to have important implications in terms of (i) correction of clinical conditions (by severity assessment); (ii) improvement of hemodynamics; (iii) possible anti-inflammatory effect; and (iv) possible improvement of oxygen metabolism in tissues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15828924     DOI: 10.1111/j.1774-9987.2005.00230.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  4 in total

1.  Binding interactions of bacterial lipopolysaccharide and the cationic amphiphilic peptides polymyxin B and WLBU2.

Authors:  Matthew P Ryder; Xiangming Wu; Greg R McKelvey; Joseph McGuire; Karl F Schilke
Journal:  Colloids Surf B Biointerfaces       Date:  2014-05-14       Impact factor: 5.268

Review 2.  Direct hemoperfusion with polymyxin B immobilized fiber for abdominal sepsis in Europe.

Authors:  Koichi Sato; Hiroshi Maekawa; Mutsumi Sakurada; Hajime Orita; Yoshihiro Komatsu
Journal:  Surg Today       Date:  2011-06       Impact factor: 2.549

Review 3.  Anti-endotoxin Properties of Polymyxin B-immobilized Fibers.

Authors:  Tohru Tani; Tomoharu Shimizu; Masaji Tani; Hisataka Shoji; Yoshihiro Endo
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 4.  Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review.

Authors:  Dinna N Cruz; Mark A Perazella; Rinaldo Bellomo; Massimo de Cal; Natalia Polanco; Valentina Corradi; Paolo Lentini; Federico Nalesso; Takuya Ueno; V Marco Ranieri; Claudio Ronco
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.